Literature DB >> 3283555

Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli.

C O Tacket1, G Losonsky, H Link, Y Hoang, P Guesry, H Hilpert, M M Levine.   

Abstract

Enterotoxigenic Escherichia coli is a common cause of traveler's diarrhea. Prophylaxis against traveler's diarrhea has been associated with side effects from bismuth subsalicylate and the development of resistance to antimicrobial agents. We undertook a double-blind controlled trial in which a bovine milk immunoglobulin concentrate with high titers of antibodies against enterotoxigenic E. coli was used as prophylaxis against E. coli challenge in volunteers. Lyophilized milk immunoglobulins were prepared from the colostrum of cows immunized with several enterotoxigenic E. coli serotypes and fimbria types, E. coli heat-labile enterotoxin, and cholera toxin. As a control, an immunoglobulin concentrate with no anti-E. coli activity was prepared. Ten volunteers received buffered immunoglobulin concentrate against enterotoxigenic E. coli, and 10 received the control immunoglobulin concentrate, dissolved in water, three times a day. No side effects were observed. On the third day of immunoglobulin prophylaxis, the volunteers were given 10(9) colony-forming units of enterotoxigenic E. coli H10407 (O78:H11). This strain produces colonization factor antigen I and heat-labile and heat-stable enterotoxins. None of the 10 volunteers receiving the immunoglobulin concentrate against E. coli had diarrhea, but 9 of the 10 controls did (P less than 0.0001). All volunteers excreted E. coli H10407. We conclude from these preliminary results that milk immunoglobulin concentrate may be an effective prophylaxis against traveler's diarrhea.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283555     DOI: 10.1056/NEJM198805123181904

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  67 in total

Review 1.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins.

Authors:  Koushik Roy; Scott Bartels; Firdausi Qadri; James M Fleckenstein
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

3.  Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate.

Authors:  D M Lyerly; E F Bostwick; S B Binion; T D Wilkins
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

4.  Could the GI tract be a better portal for antibody therapy?

Authors:  S J Green; Jon Brendsel
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 5.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

6.  The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease.

Authors:  Michael J Darsley; Subhra Chakraborty; Barbara DeNearing; David A Sack; Andrea Feller; Charlotte Buchwaldt; A Louis Bourgeois; Richard Walker; Clayton D Harro
Journal:  Clin Vaccine Immunol       Date:  2012-10-03

7.  Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli.

Authors:  T S Coster; M K Wolf; E R Hall; F J Cassels; D N Taylor; C T Liu; F C Trespalacios; A DeLorimier; D R Angleberger; C E McQueen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

8.  A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder.

Authors:  Benjamin L Handen; Raun D Melmed; Robin L Hansen; Michael G Aman; David L Burnham; Jon B Bruss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2009-01-16

9.  Multiplex PCR assay and simple preparation method for stool specimens detect enterotoxigenic Escherichia coli DNA during course of infection.

Authors:  S Stacy-Phipps; J J Mecca; J B Weiss
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

10.  The EtpA exoprotein of enterotoxigenic Escherichia coli promotes intestinal colonization and is a protective antigen in an experimental model of murine infection.

Authors:  Koushik Roy; David Hamilton; Kenneth P Allen; Mildred P Randolph; James M Fleckenstein
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.